

IN THE CLAIMS:

This listing of claims will replace all prior versions, and listing, of claims in the application:

1. (Cancelled)
2. (Currently amended; changes from last submission of amendments expressly shown)
A method for inhibiting the non-covalent association of membrane attack complex and circulating immune complex, the method comprising:

Administration of an inhibitor [selected from the group consisting of]
comprising a monoclonal antibody having specificity for the membrane attack complex, in patients suffering from at least one complement or circulating immune complex mediated disease; wherein the inhibitor inhibits the association.

- 3-17. (Cancelled)

18. (Currently amended; changes from last submission of amendments expressly shown)

A method of reducing disease symptoms in an individual in need thereof, the method comprising:

Identifying an individual in need of reducing the symptoms caused by increased complement fixation on circulating immune complex; said identifying including the steps of testing the individual to determine the presence of inflammation or tissue necrosis; [wherein the symptoms of increased complement fixation on circulating immune complex are selected from the group consisting of inflammation and tissue necrosis;] and

[Wherein the reducing disease symptoms is accomplished by]

[a] Administering a composition comprising a monoclonal antibody having specificity for the membrane attack complex,

Wherein the monoclonal antibody inhibits complement fixation on circulating immune complex.

19. (Cancelled)

20. (Previously presented) A method in accordance with claim 18,
wherein the administering comprises inoculating the individual with the immune complex and composition,

wherein the symptoms are reduced.

21. (Previously presented) The method of claim 2 wherein the disease is selected from the group consisting of systemic lupus erythematosus, rheumatoid arthritis, cardiovascular diseases, kidney diseases and autoimmune diseases.

22-23. (Cancelled)

24. (Newly presented) A method of reducing disease symptoms in an individual in need thereof, the method comprising:

identifying an individual in need of reducing the symptoms caused by increased complement fixation on circulating immune complex, said identifying including the steps of testing the individual to determine the presence of inflammation or tissue necrosis;

administering a composition comprising a monoclonal antibody having specificity for the membrane attack complex,

wherein the monoclonal antibody inhibits complement fixation on circulating immune complex;

wherein the administering comprises inoculating the individual with the immune complex and composition,

wherein the symptoms are reduced; and

wherein the disease is selected from the group consisting of systemic lupus erythematosus, rheumatoid arthritis, cardiovascular disease, kidney disease, and autoimmune disease.

25. (Newly presented) The method of claim 24 wherein the disease is systemic lupus erythematosus.

26. (Newly presented) The method of claim 24 wherein the disease is rheumatoid arthritis.

27. (Newly presented) The method of claim 24 wherein the disease is cardiovascular disease.

28. (Newly presented) The method of claim 24 wherein the disease is kidney disease.

29. (Newly presented) The method of claim 24 wherein the disease is autoimmune disease.